Transaction Expected to Close Towards the End
of Calendar Year 2024
Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling
the development and supply of better treatments for patients
worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life
sciences investment firm, today announced that the European
Commission (EC) has granted unconditional approval for the pending
transaction under which Novo Holdings will acquire Catalent.
“We are pleased to have received European Commission approval,
which is a significant milestone toward completing our pending
transaction with Novo Holdings,” said Alessandro Maselli, President
and Chief Executive Officer of Catalent. “I am deeply grateful for
the ongoing commitment and efforts of the Catalent team. There is
tremendous positive momentum underway at Catalent, and I believe
that our future is even brighter as a private company with the
support of Novo Holdings.”
“With the European Commission’s approval, we are one step closer
to delivering the benefits of this transaction,” said Jonathan
Levy, Senior Partner, Novo Holdings. “We look forward to supporting
Catalent in its next chapter as it continues to create value for
stakeholders, ultimately delivering better outcomes for the
Company’s customers and the patients they serve.”
The transaction is expected to close towards the end of calendar
year 2024, subject to the satisfaction of other customary closing
conditions, including receipt of all requisite regulatory
clearances.
For additional information associated with the transaction,
please visit transaction.catalent.com.
Advisors
Citi and J.P. Morgan served as financial advisors to Catalent.
Skadden, Arps, Slate, Meagher & Flom LLP served as legal
advisor to Catalent and Jones Day served as legal advisor to the
Catalent Board of Directors. Morgan Stanley & Co. LLC served as
financial advisor to Novo Holdings. Goodwin Procter LLP and
Linklaters LLP served as legal advisors to Novo Holdings. Arnold
& Porter Kaye Scholer LLP and Davis Polk & Wardwell LLP
served as legal advisors to Novo Nordisk.
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT), is a global leader in enabling
pharma, biotech, and consumer health partners to optimize product
development, launch, and full life-cycle supply for patients around
the world. With broad and deep scale and expertise in development
sciences, delivery technologies, and multi-modality manufacturing,
Catalent is a preferred industry partner for personalized
medicines, consumer health brand extensions, and blockbuster drugs.
Catalent helps accelerate over 1,500 partner development programs
and launch over 150 new products every year. Its flexible
manufacturing platforms at over 50 global sites supply nearly 70
billion doses of nearly 8,000 products annually. Catalent’s expert
workforce of approximately 17,000 includes more than 3,000
scientists and technicians. Headquartered in Somerset, New Jersey,
the company generated approximately $4.4 billion in revenue in its
2024 fiscal year. For more information, visit www.catalent.com.
About Novo Holdings A/S
Novo Holdings is a holding and investment company that is
responsible for managing the assets and the wealth of the Novo
Nordisk Foundation. The purpose of Novo Holdings is to improve
people's health and the sustainability of society and the planet by
generating attractive long-term returns on the assets of the Novo
Nordisk Foundation.
Wholly owned by the Novo Nordisk Foundation, Novo Holdings is
the controlling shareholder of Novo Nordisk A/S and Novonesis A/S
(formerly Novozymes A/S) and manages an investment portfolio with a
long-term return perspective. In addition to managing a broad
portfolio of equities, bonds, real estate, infrastructure and
private equity assets, Novo Holdings is a world-leading life
sciences investor. Through its Seed, Venture, Growth, Asia,
Planetary Health and Principal Investments teams, Novo Holdings
invests in life science companies at all stages of development. As
of year-end 2023, Novo Holdings had total assets of EUR 149
billion. www.novoholdings.dk
Forward-Looking Statements
This press release, and any related oral statements, may include
both historical and forward-looking statements and guidance. All
statements other than statements of historical fact, are, or may be
deemed to be, forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These
forward-looking statements generally can be identified by the use
of statements that include phrases such as “believe,” “expect,”
“anticipate,” “intend,” “estimate,” “plan,” “project,” “predict,”
“hope,” “foresee,” “likely,” “may,” “could,” “target,” “will,”
“would,” or other words or phrases with similar meanings.
Similarly, statements that describe Catalent’s objectives, plans,
or goals are, or may be, forward-looking statements. These
statements are based on current expectations of future events. If
underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could vary materially
from Catalent’s expectations, projections, and guidance. Some of
the factors that could cause actual results to differ materially
from forward-looking statements include, but are not limited to,
the pending merger of Catalent with an affiliate of Novo Holdings
(the “Merger”), the completion of the Merger on anticipated terms
and timing, including obtaining antitrust and other regulatory
approvals and clearances, the satisfaction of other conditions to
the completion of the Merger, potential litigation relating to the
Merger that could be instituted by or against Catalent, Novo
Holdings or their respective affiliates, directors or officers,
including the effects of any outcomes related thereto, the risk
that disruptions from the Merger will harm Catalent’s
relationships, and certain restrictions during the pendency of the
Merger that may impact Catalent’s ability to pursue attractive
business opportunities or strategic transactions.
These forward-looking statements speak only as of the date of
this press release or as of the date they are made, and Catalent
does not undertake to and specifically disclaims any obligation to
publicly release the results of any updates or revisions to these
forward-looking statements that may be made to reflect future
events or circumstances after the date of such statements or to
reflect the occurrence of anticipated or unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241206387579/en/
Catalent Investor Contact: Paul Surdez +1 (732)
537-6325 investors@catalent.com Media Contact: Laura Hortas
+1 (609) 240-7025 media@catalent.com Novo Holdings (Global
inquiries) Marie-Louise Jersin, Senior Communications Partner (US
inquiries) Dora Gonzalez, Public Relations Specialist
novoholdingsmedia@novo.dk
Catalent (NYSE:CTLT)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Catalent (NYSE:CTLT)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
